A Phase 1 Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer

Condition:   Gastric and Gastroesophageal Junction Cancer Intervention:   Drug: AMG 199 Sponsor:   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials